Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C

Table 2 Patient demographic and clinical characteristics of all patients within the two hospital groups

Characteristic	KLH				MM				Total
	Group 2		Group 1		Group 2		Group 1		KLH	MM
	N	%	N	%	N	%	N	%
Number of patients	172	64.4	95	35.6	166	64.8	90	35.2	267	256
Sex
Male	141	82	77	81.1	133	80.1	77	85.6	218	210
Female	31	18	18	18.9	33	19.9	13	14.4	49	46
Mean age in years	37.6		36.8		35.6		47.9
Tumor status
Primary	100	58.1	44	46.3	102	61.4	44	48.9	144	146
Recurrent	72	41.9	51	53.7	64	38.6	46	51.1	123	110
Previous treatment in patients with recurrent tumors at baseline
Current single post-TURBT intravesical chemotherapy	2		3		1		1		5	2
Previous single post-TURBT intravesical chemotherapy	8		2		2		1		10	3
Local adjuvant intravesical therapy	20		11		12		15		31	27
Other therapy	3								3	3
No therapy other than TURBT	39		35		49		29		74	78
Tumor stage
pTa	132	76.7	84	88.4	113	68.1	71	78.9	216	184
pT1	40	23.3	11	11.6	53	31.9	19	21.1	51	72
Tumor grade
1	54	31.4	34	35.8	47	28.3	32	35.6	88	79
2	95	55.2	53	55.8	87	52.4	47	52.2	148	134
3	23	13.4	8	8.4	32	19.3	11	12.2	31	43
Number of tumors
Single	60	34.9	29	34.9	57	34.3	26	28.9	89	83
Multiple	112	65.1	66	69.5	108	65.1	64	71.1	178	172
Unknown					1					1

KLH Keyhole Limpet Hemocyanin, MM mitomycin C, TURBT transurethral resection of bladder tumor

ISSN: 1745-6215